.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
ZeroHarm Sciences recently raised Rs 65 crore to scale its innovative plant-based nutraceutical brand. Consequently, this capital infusion from Kotak Life Sciences Fund and Alkemi Growth Capital marks a major milestone. The company intends to enhance its research capabilities and global reach.
Specifically, ZeroHarm uses proprietary nano-formulation technology to increase the bioavailability of its supplements. This method ensures that herbal actives are absorbed more effectively by the body. Furthermore, the firm is building India's first \"Trust over Promise\" health platform. This model correlates supplement use with measurable diagnostic results.
Additionally, the startup plans to enter markets in the US, UK, and the Middle East. ZeroHarm maintains a vertically integrated ecosystem, covering extraction, R&D, and manufacturing. Notably, this structure allows for strict quality control and standardized health outcomes. Because of these factors, investors see high potential in the company’s science-led approach.
Q1: What is the \"Trust over Promise\" platform?
The \"Trust over Promise\" platform allows customers to see measurable health outcomes through before-and-after diagnostic testing.
Q2: How does nano-formulation technology benefit patients?
Nano-formulation breaks down herbal actives into ultra-fine particles, which significantly improves their absorption and efficacy compared to traditional supplements.
Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or replace professional judgment. Refer to the latest local and national guidelines for clinical practice.
References
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
ZeroHarm Sciences raised Rs 65 crore to expand its plant-based nutraceutical brand using nano-technology and a diagnostic-led health outcome model....
4 months ago
A recent cross-sectional study of 15.2 million adults reveals a goiter prevalence of 1.3-2.5%. This detailed analysis explores why women and older adults are at higher risk, the dominance of non-toxic multinodular subtypes, and the clinical implications for primary care and endocrinology.
Today
A deep dive into the National Family Health Survey (NFHS-6) data showing a sharp rise in surgical deliveries in Karnataka, the public-private healthcare divide, clinical risks of elective surgeries, and the urgent need for standardized medical guidelines to safeguard maternal and newborn health.
Today
A breakthrough study has utilized computational fluid dynamics to develop an optimized multi-stage drainage cannula for VA ECMO. By refining side-hole placement and angles, the new design significantly reduces stagnant blood volumes and increases flow efficiency, potentially lowering the risk of thrombosis.
Today
Perilunate dislocations are challenging orthopedic emergencies. This article explores a novel 4-anchor suture tape internal bracing technique that eliminates the need for K-wire retention, facilitating earlier recovery and excellent long-term functional outcomes as demonstrated in a recent clinical case.
Today
An international panel of experts has officially recognized fatty pancreas disorder as a distinct disease in the Melbourne Consensus. Learn about its diagnostic criteria using MRI, its pathophysiological association with type 2 diabetes and cancer, and evidence-based lifestyle and pharmacological interventions.
Today
